Hospital Infections News
-
Vancomycin-Resistant Enterococci (VRE) in Healthcare Settings Discussed in New Online Video
The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses vancomycin-resistant enterococci, commonly referred to as VRE, which are bacteria that can cause various healthcare-associated infections (HAIs). “In the CDC’s 2019 Antibiotic Resistance Threats in the United States report, VRE was ...
-
Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens
An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...
-
Aspergillus Infection Risks in Hospitals, Homes and Buildings
Aspergillosis is a potentially life-threatening condition caused by a fungal pathogen known as Aspergillus. It is a common type of mold found outdoors and in indoor environments. It can be found at excessive concentrations indoors when buildings suffer water damage or elevated humidity levels. Fortunately, most healthy people breathe Aspergillus spores without infection concerns. However, some ...
-
Infection Prevention through Clean Water: How Healthcare Facilities Can Mitigate Healthcare-Associated Infections from Water
Healthcare-associated infections or HAIs are infections people get while they are receiving health care for another condition. These infections can happen in all types of healthcare settings and are a significant cause of patient illness and death. According to the Centers for Disease Control and Prevention (CDC), 1 in 31 patients experience a healthcare-associated infection on any given day, ...
-
Infection Control Resources to Safeguard Patients and Building Occupants from Acinetobacter and Other Pathogens
The Centers for Disease Control and Prevention describe Acinetobacter as a group of bacteria commonly found in the environment in places like soil and water. While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are ...
-
Mitigating Exposure Risks to Mucormycetes to Protect Patients, Workers, and Building Occupants
Mucormycetes are a group of fungi that can cause a rare but serious fungal infection known as mucormycosis reports the Centers for Disease Control and Prevention (CDC). These fungi live in soil and decaying organic matter. People with a weakened immune system could get mucormycosis by inhaling fungal spores or if they enter the skin through an injury. Types of mucormycosis listed by CDC include: ...
-
Staphylococcus aureus and Mitigating Exposure Risks in Occupational, Healthcare and Community Settings
Frequently referred to as staph, Staphylococcus aureus is a type of bacteria that is commonly found on the skin and hair, as well as in the nose and throat of people and animals. In fact, the Centers for Disease Control and Prevention (CDC) reports that about 30% of people carry Staphylococcus aureus in their nose. While most of the time staph does not cause harm to healthy individuals, it has ...
-
Mitigating Aspergillus Infection Risks in Hospitals and Buildings across Puerto Rico
A potentially life-threatening condition known as aspergillosis is caused by a fungal pathogen named Aspergillus. It is a common type mold that can often be found outdoors and in indoor environments that have suffered water damage or elevated humidity levels. Fortunately, most healthy people breathe Aspergillus spores without infection concerns. However, some species are known to be a serious ...
-
TOMI Secures Vizient Contract as an Approved Supplier of SteraMist Systems for Nationwide Healthcare Networks
TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company has entered into a contract with Vizient, Inc. increasing TO Mi's presence in the U.S. healthcare system. Vizient is the largest group purchasing organization (GPO) in the healthcare industry supplying around $100 billion in ...
-
Protecting Patients, Workers and Building Occupants from Staphylococcus aureus and Other Pathogens in Puerto Rico
Staphylococcus aureus is a type of bacteria that has long been recognized as a cause of disease. Frequently referred to as staph, it is commonly found on the skin and hair, as well as in the nose and throat of people and animals. The Centers for Disease Control and Prevention (CDC) even reports that about 30% of people carry Staphylococcus aureus in their nose. Most of the time, staph does not ...
-
Tomi Environmental Solutions, Inc. Reports 40% Increase in Fourth Quarter Revenue
Robust Pipeline in Life Sciences Sector Positions Business for Growth in 2023 – Significantly Reduced SG&A in The Quarter and Year – 58% Reduction in Net Loss and Slight Adjusted EBITDA Loss in The Fourth Quarter Reflect Operating Leverage In Business Model As Company Scales – FREDERICK, Md., March 16, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® ...
-
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2022 Financial Results on March 16, 2023
FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report results for the fourth quarter ended December 31, 2022, after the close of the financial markets on Thursday, March 16, 2023 and will hold a conference call at ...
-
TOMI to Attend Three Leading Pharmaceutical Conferences in the First Quarter of 2023
FREDERICK, Md., Jan. 25, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that TOMI will present its SteraMist brand of products at three upcoming International Society for Pharmaceutical Engineering (ISPE) Conferences in the first quarter of 2023: The ISPE ...
-
TOMI Expands Globally with Purchase from National Health Services (NHS) Wales
FREDERICK, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, announces that the National Health Services (NHS) Wales purchased SteraMist ionized Hydrogen Peroxide (iHP) technology further expanding presence in Great Britain. NHS Wales is a publicly funded ...
-
7 December 2022 - FDA/CDC highlight need for infection preventions
Particular support for decolonisation of pathogens which is the approach taken by its XF-73 Nasal programme Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, today reports on the publication of findings from the US Food and Drug Administration (FDA) and US Centers for ...
-
XF-73 Nasal Phase 3 development plans finalised
Targeting peak sales potential of $1 billion in the major markets Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that it has now finalised plans for its Phase 3 studies for its late-stage clinical asset, XF-73 Nasal. Highlights Discussions held ...
-
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
-
XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...
-
A project led by Vaxdyn receives funding from Next Generation EU Funds
The project “AMReady: Development and manufacturing of vaccines for alleviation and preparedness for anti-microbial resistance global health crisis”, to be executed in 2021-2024 with a total budget of 1.4 million euro has been awarded funding by the competitive program Lineas Estratégicas de Colaboración Público-Privada 2021 of the State Research Agency of the ...
-
How BioVigil Reduces Staff Absenteeism in Hospitals
Staff absences are a problem for any employer, but are particularly challenging in hospitals and other healthcare settings. Unplanned staff absences can leave supervisors struggling to fill shifts and overwork employees who have to cover for their peers. These drops in productivity or gaps in care can put patients at risk. To combat employee absenteeism and its effects, hospitals need to ...
By BioVigil
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you